Ground-breaking therapy comes with distinct challenges

Print Friendly, PDF & Email


Attendees at the 13th NCCN
hematology congress
Photo courtesy of NCCN
Two chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel (Yescarta ®) and tisagenlecleucel (Kymriah™)—are already approved in B-cell lymphoma by the U.S. Food and Drug Administration. A third, lisocabtagene maraleucel, will most likely be approved before too long. Despite differences, they all have high... [Read Article]
Print Friendly, PDF & Email

Novel agents changing treatment algorithm in AML

Print Friendly, PDF & Email


Richard Stone, MD
Photo courtesy of NCCN
Recent drug approvals for acute myeloid leukemia (AML) have greatly expanded options for treating patients, according to a presentation at the NCCN 13th Annual Congress: Hematologic Malignancies. Richard M. Stone, MD, of the Dana-Farber Cancer Institute in Boston, M.A., gave this presentation, providing some guidance for how... [Read Article]
Print Friendly, PDF & Email

Current management of AML patients

Print Friendly, PDF & Email


Attendees at the 13th NCCN
hematology congress
Photo courtesy of NCCN
A presentation at the NCCN 13th Annual Congress: Hematologic Malignancies outlined current practices for managing patients with acute myeloid leukemia (AML). Richard M. Stone, MD, of the Dana-Farber Cancer Institute in Boston, M.A., noted that management of AML now includes increased screening of... [Read Article]
Print Friendly, PDF & Email

Metabolic changes in T cells may limit CAR potential in kids

Print Friendly, PDF & Email


David Barrett, MD, PhD
Researchers analyzed peripheral blood T cells from 157 pediatric cancer patients at diagnosis and after chemotherapy and found the potential to produce effective chimeric antigen receptor (CAR) T cells declined with each cycle of chemotherapy. This was also true for acute lymphoblastic leukemia (ALL) and Wilms’ tumor, which had high CAR... [Read Article]
Print Friendly, PDF & Email

DLBCL survivors at greater risk of autoimmune, infectious diseases

Print Friendly, PDF & Email


Poster session at ASH 2017
Photo courtesy of ASH
© Todd Buchanan 2017
A population-based study indicates that, compared to other cancer survivors, patients who survive diffuse large B-cell lymphoma (DLBCL) have an increased risk of autoimmune and infectious diseases. For example, investigators found the risk of being diagnosed with impaired humoral immunity was... [Read Article]
Print Friendly, PDF & Email

Ixazomib/lenalidomide maintenance promising after ASCT in MM

Print Friendly, PDF & Email


Attendees at ASH 2017
Photo courtesy of ASH
© Todd Buchanan 2017
Adding ixazomib to lenalidomide as maintenance therapy for newly diagnosed multiple myeloma (MM) patients after upfront autologous stem cell transplant (ASCT) appears promising, according to an update of a phase 2 study. The oral doublet produced an overall response rate of... [Read Article]
Print Friendly, PDF & Email

Update reveals ongoing responses in ZUMA-1

Print Friendly, PDF & Email


Sattva S. Neelapu, MD
Photo courtesy of ASH
© Phil McCarten 2017
The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; KTE-C19) is showing consistent, ongoing responses more than a year after infusion. An updated analysis of the phase 1/2 ZUMA-1 trial showed that 42% of patients who received axi-cel maintained an... [Read Article]
Print Friendly, PDF & Email

Study highlights need for induction strategy in elderly, frail MM patients

Print Friendly, PDF & Email


Sign at the 2017
ASH Annual Meeting
Initial results of the phase 2 HOVON-126 trial in newly diagnosed multiple myeloma (MM) patients have highlighted the need for an induction strategy in elderly and frail patients. The trial showed high overall response rates (ORRs) after induction with ixazomib, thalidomide, and low-dose dexamethasone. However, 62%... [Read Article]
Print Friendly, PDF & Email

bb2121 induces durable, deepening responses in MM patients

Print Friendly, PDF & Email


James N. Kochenderfer, MD
Photo courtesy of ASH
© Phil McCarten 2017
Updated results from a phase 1 trial have shown that bb2121, a chimeric antigen receptor (CAR) T-cell product, can induce durable, deepening responses in patients with relapsed/refractory multiple myeloma (MM). Responses continue to improve from very good partial responses to... [Read Article]
Print Friendly, PDF & Email

Risk stratification may be possible with JCAR017

Print Friendly, PDF & Email


Attendees at ASH 2017
Photo courtesy of ASH
© Scott Morgan 2017
Data suggest a therapeutic window may exist for CAR T-cell expansion with JCAR017, according to a preliminary model. In a core set of 67 patients with diffuse large B-cell lymphoma (DLBCL) who had received JCAR017 in the TRANSCEND NHL 001 trial, investigators... [Read Article]
Print Friendly, PDF & Email

Primary analysis confirms interim findings of CTL019 in DLBCL

Print Friendly, PDF & Email


Stephen J. Schuster, MD
Photo courtesy of ASH
© Phil McCarten 2017
The first chimeric antigen receptor (CAR) T-cell therapy approved in the US to treat children and young adults with leukemia is also producing high response rates in lymphoma, according to investigators of the JULIET trial. They reported that tisagenlecleucel (formerly CTL019) produced... [Read Article]
Print Friendly, PDF & Email

Ibrutinib sustains efficacy in CLL at 4-year follow-up

Print Friendly, PDF & Email


Ibrutinib (Imbruvica)
Photo courtesy of Janssen
The 4-year follow-up of the RESONATE trial suggests ibrutinib may provide long-term efficacy in previously treated patients with chronic lymphocytic leukemia (CLL). The median progression-free survival (PFS) has not yet been reached in this trial, regardless of high-risk cytogenetics, according to Jennifer Brown, MD, PhD, of the Dana-Farber... [Read Article]
Print Friendly, PDF & Email

BCMA emerging as a promising target in MM

Print Friendly, PDF & Email


Bone marrow aspirate showing plasma cells of multiple myeloma
The B-cell maturation antigen (BCMA) is emerging as a promising target in multiple myeloma (MM), according to Adam D. Cohen, MD, of the University of Pennsylvania in Philadelphia. BCMA is highly expressed on MM cells and, with its 2 ligands, is responsible for maintaining... [Read Article]
Print Friendly, PDF & Email